|
Gastroenterology & Hepatology
Urinary PGE-M, a Possible Biomaker of Tobacco Smoke-induced Lung Injury
Investigator: Dannenberg, Andrew J
Phone Number: x6-4911
Syringe Exchange Peer Mobilization Intervention
Investigator: Edlin, Brian R
Phone Number: 746-4400
A 12-Week, Randomized, Double-blind, Placebo-Controlled Study of Asimadoline in Subjects with Irritable Bowel Syndrome (IBS)
Investigator: Frissora, Christine L.
Phone Number: x6-4016
CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase II Randomized Open Label, Multi-Center, Parallel
Arm, Controlled Trial of CPG
Investigator: Gambarin-Gelwan, Maya
Phone Number: 746-4400
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics
and ...
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A Phase 2 Study of VX-950 in Combination with Peginterferon Alfa-2a (Pegasys), With and Without Ribavirin (Copegus) in Subjects
with Hepatits C
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate
(DF) Monotherapy Versus
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A Phase IB Randomized Trial of CPG 10101 Alone, with Interferon, Ribavirin or Interferon and Ribavirin in the Treatment of
Relapssed HCV Subjects
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive
Chronic Hepatitis B...
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A randomized, double-blind, placebo-controlled, multicenter, time-lagged, parallel, multiple-dose, escalating dose study to
assess safety/tolerability
Investigator: Jacobson, Ira M
Phone Number: x6-2115
An Open-label Study of the Efficacy of Daily Interferon Alfacon-1 (Infergen, CIFN) plus Ribavirin in Hepatitis C Infected
Patients Who are....
Investigator: Jacobson, Ira M
Phone Number: x6-2115
Comparison of PEG-Intron 1.5mc/kg/wk plus REBETOL vs PEG-Intron 1mcg/kg/wk plus REBETROL vs PEGASYS 180mcg/wk plus COPEGASYS
in previously untreated
Investigator: Jacobson, Ira M
Phone Number: x6-2115
PEG-Intron/Rebetol vs PEG-Intron/SCH 503034 With and Without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin
Nonresponders:...
Investigator: Jacobson, Ira M
Phone Number: x6-2115
Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of MN283 and the Combination of Pegylated
Interferon Plus NM283, in
Investigator: Jacobson, Ira M
Phone Number: x6-2115
SCH503034 in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1. A Phase 2 Safety and Efficacy
Study. (P03523)
Investigator: Jacobson, Ira M
Phone Number: x6-2115
A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Daily Interferon Alfacon-1 plus Ribavirin
in Hepatitis C...
Investigator: Lake-bakaar, Gerond V
Phone Number: x6-2115
IRHC-001: A Phase 3, Randomized, Open-label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 plus
Ribavirin Administered da
Investigator: Lake-bakaar, Gerond V
Phone Number: x6-2115
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response)
and Safety of 360 ...
Investigator: Lake-Bakaar, Gerond V
Phone Number: x6-2115
A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium dfficile-Associated
Diarrhea (CDAD)
Investigator: Maltz, Charles
Phone Number: 746-4400
A Multi-center, Randomized, Blinded, Placebo-controlled, Phase II Study of Human Monolocal Antibody to IL 12p40 (CNTO 1275)
in Subjects with Crohn's..
Investigator: Scherl, Ellen J
Phone Number: x821-0756
A Mutlicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation
and Dosing Regimen
Investigator: Scherl, Ellen J
Phone Number: x821-0756
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory
Investigator: Scherl, Ellen J
Phone Number: x821-0756
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter study of Visilizumab in subjects with Intravenous Steroid
Refractory ...
Investigator: Scherl, Ellen J
Phone Number: x821-0756
A Phase III, Multicenter, Open Label Trial to Evaluate the Long Term Safety and Tolerability of a New Balsalazide Disodium
Tablet Formulation in ...
Investigator: Scherl, Ellen J
Phone Number: x821-0756
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for
Intravenous ...
Investigator: Scherl, Ellen J
Phone Number: x821-0756
Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNN Monoclonal Antibody Adalimumab in Patients with Moderate
to Severe Crohn's Disease..
Investigator: Scherl, Ellen J
Phone Number: x821-0756
Ph.3B Multicenter,Open Label Induction & Double Blind Comparison of 2 Maintenance Scheds. Evaluating Clinical Benefit & Tolerability
of Certolizumab..
Investigator: Scherl, Ellen J
Phone Number: x821-0756
A Phase III Randomized, Placebo-controlled Study of Sorafenib In Patients with Hepatocellular Carcinoma
Investigator: Schilsky, Michael L
Phone Number: x6-4129
PROTECT-Pegylated Interferon alfa-2b and Ribavirin after Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis
C Recurrence Therapy
Investigator: Schilsky, Michael L
Phone Number: x6-4129
Phase IB Randomized Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients With Barrett's Esophagus
Investigator: Schnoll-Sussman, Felice H
Phone Number: 746-4400
A Multi-Center Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin
550 MG BID
Investigator: Sigal, Samuel H
Phone Number: x6-4129
Assessment and clinical utility of non-invasive parameters of inflammatory activity in patients with chronic hepatitis B
Investigator: Sigal, Samuel H
Phone Number: x6-4129
TPL102357 A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, ...SB-497115-GR...
Investigator: Sigal, Samuel H
Phone Number: x6-4129
The Effect of Rifaximin on Bacterial Overgrowth an Hepatic Encephalopathy
Investigator: Sigal, Samuel H
Phone Number: x6-4129
A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of PEGASYS 180 ºg plus Copegus
1000 (<75 kg) or 1200
Investigator: Talal, Andrew Henry
Phone Number: 746-4400
|
